The syndrome of motor restlessness -a treatable but underrecognised disorder The Rarely reported causes of akathisia include bilateral prefrontal lobe damage secondary to traumatic brain injury," sudden cessation of cigarette smoking and treatment with electroconvulsive therapy (ECT). Nicotine withdrawal12 has been implicated in the occurrence of psychomotor agitation in a terminally ill patient with cancer. The symptoms were reversed with the use of nicotine skin patches. However, the association between ECT and akathisia is less clear. Although ECT was reported to have triggered the syndrome in one patient,13 other authors14 claimed that it improved drug-resistant akathisia in another subject.
The underlying pathophysiological mechanism of akathisia is thought to be imbalance between the cortical and nigrostriatal dopaminergic innervation in favour of increased functional activity of the mesolimbic and nigrostriatal systems, in particular the nucleus accumbens. A syndrome resembling akathisia occurs following stereotactic lesions of the dopaminergic pathways in the frontal lobes in experimental animals'5 and has also been reported in a patient with acquired traumatic damage of the prefrontal cortex.11 The association of akathisia with the use of some dopamine agonists and the symptomatic improvement following treatment with monoamine-depleting drugs also lend support to this hypothesis.
Iron deficiency anaemia is frequently seen in patients with neuroleptic-induced tardive akathisia'6 but this association has not been observed consistently in the acute form of the syndrome.17 The pathophysiologic significance of the low serum iron in chronic akathisia is not fully understood. Gold and Lenox18 have recently reviewed the evidence confirming that neuroleptic drugs mobilise iron from peripheral stores and promote its deposition in the basal ganglia and postulated that the excess iron modifies dopaminergic neurotransmission in the nigro-striatal system by binding preferentially to D2 receptors.
Differential diagnosis
The main conditions which need to be distinguished from akathisia are the restless legs syndrome and anxiety states. In addition, akathisia occurring in patients with Parkinson's disease may also be confused with dyskinesias.
The restless legs syndrome is a disorder of unknown aetiology which occurs in 5% of the healthy adult population. It is particularly common during pregnancy with one in every three women affected. In elderly subjects with sleep disturbances the syndrome accounts Diagnostic criteria of the restless leg syndrome * motor agitation, typically characterised by intense desire to walk or move legs, often accompanied by muscle cramps and/ or unpleasant skin sensation * symptoms worse at rest and improved by movement * symptoms absent or minimal in the earlier part of the day but worsen in the evening and at night * a normal neurological examination * onset in late middle life or old age Box 2 for 23% of cases.20 Restless legs syndrome is characterised by muscle discomfort, pain and restlessness. The patient often describes a strange crawling sensation in the calf muscles and occasionally similar symptoms in the upper limbs. These symptoms are relieved by walking2l (box 2).
Unlike akathisia, which ceases during sleep, the restless legs syndrome occurs mostly at night and is sometimes associated with nocturnal myoclonus and muscle cramps. Treatment with dopaminergic drugs results in long-term remission of symptoms.22 Baclofen (20-40 mg/day) is also effective. The response to these drugs may be used as a therapeutic test to confirm the diagnosis.
The hyperactivity associated with anxiety states is often indistinguishable from akathisia, especially in psychotic patients taking neuroleptic drugs. However, the sympathetic overactivity, eg, excessive sweating, palpitations, hyperventilation, tremulousness and dilated pupils, which is characteristic of anxiety and panic attacks is not seen in patients with akathisia. Akathisia is also difficult to diagnose in patients with bipolar affective disorders treated with antidepressant and other medication as the psychomotor agitation associated with drug-induced akathisia could be confused with spontaneous mania, although akathisia is usually milder and short-lived. In addition, patients with spontaneous mania usually have more severe delusions, hallucinations and bizarre behaviour.23
Dyskinesias are a common complication of long-term treatment with antiparkinsonian drugs. In contrast to akathisia, these involuntary movements are often unilateral and occur on the side of the body which is affected by the Parkinson's disease. When the disease is bilateral the dyskinesia is usually more pronounced in the more severely affected arm and leg. The oro-facial musculature is usually also affected. As a rule the dyskinesias occur or increase in severity approximately 1 -2 hours after each dose of the antiparkinsonian medication but are sometimes less predictable, especially in patients with advanced disease.
Management
Withdrawal of the drug causing akathisia often results in rapid symptomatic relief. However, in some patients symptoms may persist for months after discontinuation of the drug. Dose reduction may be sufficient. It has been suggested that the combination of monoamine oxidase inhibitors with fluoxetine or L-tryptophan is associated with an increased risk of developing akathisia.24 It is logical, therefore, to avoid co-prescribing these drugs. When these options are not available or ineffective, various treatments may be tried, including anticholinergic agents, fl-blockers, benzodiazepines, 5-HT receptor antagonists, and mianserin.
Propranolol has been reported to be effective in the treatment of the syndrome of motor restlessness. In a randomised placebo-controlled study, Alder et a125 found a significant clinical improvement by the third to fifth day of treatment with either propranolol (80 mg/day) or benztropine (6 mg/day). Akathisia associated with the use of serotonin re-uptake inhibitors may be prevented or reduced with the concomitant treatment with alprazolam.26 Antiserotoninergic drugs may also be useful in the treatment of akathisia. In an open clinical trial, Weiss et a127 have shown that cyproheptadine given in a dose of 16 mg/day over four days was effective in all 17 patients treated for neurolepticinduced akathisia. Lithium-induced akathisia was claimed to be particularly responsive to mianserin.28 Although low serum iron is commonly associated with neurolepticinduced tardive akathisia, the value of iron supplements in the patients is doubtful and may even be harmful.
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